Fosun Diagnostics to Market Miacom's Molecular Beacon Assays in Asia | GenomeWeb

NEW YORK (GenomeWeb) — Miacom Diagnostics and Fosun Diagnostics said today that they have partnered to market Miacom's molecular beacon-based diagnostic assays to the Chinese and broader Asian markets.

Under the agreement, Shanghai-based Fosun, the diagnostic division of Shanghai Fosun Pharmaceutical, will market Dusseldorf, Germany-based Miacom's proprietary multiplex assays for the detection of sepsis- and pneumonia-related pathogens.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.